FDA Avandia Restrictions
Europe and the United States drug regulators announced on September 23, 2010 that the controversial diabetes medicine, Avandia, would no longer be available to the public.
Sales of the drug is suspended completely in Europe, while in the United States patients are allowed to access the Avandia only if their physicians and themselves consent that every other diabetes drug have been exhausted, and if patients consent to use the drug while being informed of its substantial health risk involving the heart. Patients now taking Avandia may continue to do so. FDA Avandia restrictions means that Avandia will be taken off the market in the US in Nov. 2011
Internal Dispute FDA Avandia
President Barack Obama’s administration is seen with a stricter line with the Food and Drug Administration’s decision on drug safety issues, even against scientific uncertainty. The agency posted on its Web site immediately internal memorandums from top staff members that in some cases offered completely conflicting instructions. As the agency’s commissioner Dr. Margaret Hamburg said, passions had increased within the agency on the Avandia resolution.
“As F.D.A. commissioner, my job would be infinitely easier if we had consensus and full scientific clarity,” she said.
FDA Avandia news should be forthcoming soon.
The resolution of the Avandia issue provided a new insight in the treatment of diabetes, a disease that is existing in almost everywhere in the world. Due to the Avandia issue, the Food and Drug Administration had publicized earlier in 2008 that it would be stricter on the approval of medicines; they will no longer approve medicine simply because they give benefits to the patients, not including the carried health risks. In the case Avandia, they will no longer approve drugs simply because they help diabetics control blood sugar levels. Instead, the F.D.A. now suggests and insists that drug makers perform long testing that would last at least two years to show that their drugs are safe to use, and do not affect the heart, as well as improve the quality or length of the lives of diabetics. These would be far tougher tests.
FDA Avandia Mis-Information
The Avandia issue also starts a new and troubling phase for drug companies. Because the health risks of Avandia was determined only after Dr. Nissen analyzed data from clinical trials that GlaxoSmithKline, the pharmaceutical company producing Avandia, had been forced to inform the public on its Web site as a result of legal settlements. Public postings are increasing in today’s time, which would mean for the drug companies that they can no longer easily hide or manipulate scientific information regarding their medicines.
The Food and Drug Administration has demonstrated the use of the powers given to them in a 2007 law, powers over drug companies and drug distributions, evidenced by their restriction of Avandia’s sales. Along with Avandia, dozens of other drugs are now sold only with special restrictions.
To clear up why the F.D.A was against the idea of only putting more warnings on Avandia’ label, director of the F.D.A.’s drug center Dr. Janet Woodcock said, “We know that labels are often not read.”
Avandia was once the largest-selling drug around the world to treat diabetes, but due to countless reported life-threatening drug side effects, mostly concerning the heart, the public as well as the authorities have done legal actions to prevent even more reports of patient injuries and deaths. Along with this, Avandia had its sales cut. Although there are still around 600 thousand people taking Avandia in the U.S., Dr. Hamburg estimates that the numbers will go down significantly with the new restrictions. Patients taking Avandia can continue to do so until they can talk to their physicians, said Dr. Joshua Sharfstein, the F.D.A.’s principal deputy commissioner. But he also stated that doctors are advised to think twice about using other medicines, for health safety reasons.
Glaxo was ordered by the F.D.A. to end their controversial test in comparing Avandia and Actos made by Takeda. The pharmaceutical company was also ordered to perform an independent assessment of the Record trial, a study of Avandia’s heart effects that the F.D.A. found with serious subjective conclusions.
A member of the advisory team, Dr. Cliffor J. Rosen said that the new guidelines brought by this incident “will protect patients while at the same time allowing those few patients who have benefited from treatment to stay on the drug.” He was grateful that the F.D.A followed through the panel’s advice concerning the issue.
Avandia was approved by the F.D.A in 1999, helping to control blood sugar levels in diabetic patients. It belongs to one class of three drugs. The first Rezulin was recalled due to its damage on the liver. Actos, the third class appears safe partially because it is seen to affect a different set of genes compared to Rezulin and Avandia.
Investigators discovered that the pharmaceutical company GlaxoSmithKline was hiding indications and scientific studies regarding Avandia’s increased heart risks. In July 2010, GlaxoSmithKline paid a $2.3 billion liability charge involving legal cases filed against them for uninformed life-threatening side effects. At that time, investors cheered the news as Glaxo tries to set a ceiling for the liabilities it incurred due to the medicine. FDA Avandia relationship have been not the best for the American people.